Natera's revenue growth is accelerating, driven by oncology volumes exceeding one million tests for a second consecutive quarter in 2026Q2, with revenue up 37.7% YoY to $752.8M. Gross margins have expanded from 56.7% in 2024Q1 to 64.5% in 2026Q2, reflecting sc...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 37.7% YoY in 2026Q2, reaching $752.8M, while gross margin improved to 64.5% from 56.7% in 2024Q1, but operating margin remained negative at -10.1% due to rising R&D and SG&A costs.
Natera issued 2026 revenue guidance of US$2.62 billion to US$2.70 billion, indicating strong growth expectations.
New clinical data on Signatera test presented at ASCO Genitourinary Cancers Symposium highlights its potential in muscle-invasive bladder cancer.
NTRA's oncology franchise, particularly Signatera MRD testing, is a key growth driver supported by increasing testing volumes.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.47+4.8% vs -$0.49 | $753M+13.8% vs $661M |
Q2 2026 May 7, 2026 | -$0.56-3.3% vs -$0.54 | $697M+12.9% vs $617M |
Q1 2026 Feb 26, 2026 | $0.35+168.3% vs -$0.51 | $666M+10.2% vs $604M |
Q4 2025 Nov 6, 2025 | -$0.64-65.9% vs -$0.39 | $592M+15.3% vs $513M |
On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, picked Uber Technologies, Inc. (NYSE:UBER).
Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference Transcript
Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark NTRA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Natera, Inc. (NTRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $390.90 | $55.98B | -257.17 | 35.9% | -9.03% | -14.32% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $247.46 | $37.44B | 45.41 | -0.78% | 18.36% | 31.08% | — | |
| $2.49 | $235.44M | 6.55 | 161.14% | 47.55% | 42.57% | — | |
| $289.05 | $4.5B | 38.39 | 8.79% | 4.13% | 24.17% | — | |
| $1.47 | $456.58M | -0.81 | 3.89% | -82.49% | -4961.74% | — |
Natera, Inc. (NTRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Natera, Inc. (NTRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 6, 2026·SEC
Jun 16, 2026·SEC
Feb 27, 2026·SEC
Get notified when NTRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Natera, Inc. (NTRA) stock FAQ — growth, dividends, profitability & financials explained
Natera, Inc. (NTRA) reported $2.71B in revenue for fiscal year 2025. This represents a 18897% increase from $14.3M in 2012.
Natera, Inc. (NTRA) grew revenue by 35.9% over the past year. This is strong growth.
Natera, Inc. (NTRA) reported a net loss of $192.3M for fiscal year 2025.
Natera, Inc. (NTRA) has a return on equity (ROE) of -14.3%. Negative ROE indicates the company is unprofitable.
Natera, Inc. (NTRA) generated $71.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
